3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment
An updated edition of the October 28, 2025, article. The global oncology market is entering a period of...
Candida Auris Genetic Breakthrough May Target Treatment
Scientists have discovered a genetic process which could unlock new ways to treat mysterious and deadly...
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
Remarkable progress has been made in the past year for the management of chronic inflammatory skin diseases, specifically atopic dermatitis (AD) and psoriasis....
ICYMI: Highlights From AHA 2025 Scientific Sessions
Our top coverage from this year’s American Heart Association (AHA) 2025 Scientific Sessions included new guideline therapies and new mono-, dual-, and poly-approach...
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy...
SUZHOU, China, Dec. 20, 2025 /PRNewswire/ — Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by...
Breakthrough blood cancer research from UChicago Medicine presented at ASH 2025
UChicago Medicine researchers made a strong impact at the 67th American Society of Hematology (ASH) Annual Meeting, held December 6–9, 2025, in Orlando, Florida....
Parkinson’s breakthrough changes what we know about dopamine
A new study led by researchers at McGill University is calling into question a long-standing idea about how dopamine influences movement. The findings suggest...
FDA Grants Breakthrough Therapy Status to JSKN003 for Advanced Ovarian Cancer...
The FDA has granted breakthrough therapy designation (BTD) to JSKN003, an investigational biparatopic HER2-targeting antibody-drug conjugate (ADC), for the treatment of adult patients...
New Drug Stalls Alzheimer’s Development in Breakthrough Trial : ScienceAlert
Growing evidence suggests that the key to treating Alzheimer's is catching it in its earliest stages. Now scientists have developed a promising new...